Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06036836
Title	Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Merck Sharp & Dohme LLC
Indications	endometrial cancer skin squamous cell carcinoma
Therapies	Lenvatinib + Pembrolizumab Lenvatinib + MK-4280A MK-4280A Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| NLD \| ITA \| FRA \| DEU \| CAN \| AUS